Georg Schett, MD, presented the latest research into CAR T cell therapy for rheumatic diseases, such as systemic lupus erythematosus & other conditions. These findings demonstrate remarkable and durable efficacy for the treatment, as well as the potential for disease remission in some patients.
Small fiber neuropathy is a common form of peripheral neuropathy with multiple potential etiologies and a varied clinical presentation. It can’t be detected by nerve conduction studies, making it an elusive and often overlooked entity. Small fiber neuropathy is well documented in several rheumatic diseases, and its symptom burden can profoundly affect quality of life….
AURORA 2, a double-blind, phase 3 study, evaluated the long-term safety, tolerability and efficacy of voclosporin compared to placebo in patients with lupus nephritis receiving an additional two years of treatment following completion of the one-year AURORA 1 study. Patients enrolled in AURORA 2 continued to receive the same treatment randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low-dose glucocorticoids. Saxena et al. propose that the rapid renal response achieved with voclosporin treatment has long-term benefits, supported by stable kidney function over the three-year treatment period.
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.
Lower HCQ Serum Levels Associated with SLE Flare, Damage & Mortality Background & Objectives: Nguyen et al. set out to assess the consequences of severe non-adherence to hydroxychloroquine (HCQ) by measuring hydroxychloroquine serum levels, risks of systemic lupus erythematosus (SLE) flares, damage and mortality over five years of follow-up. Methods: The Systemic Lupus Erythematosus International…
At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
Materne et al. aimed to compare the risk of infection among patients with non-renal SLE using the injectable immunosuppressant belimumab vs. an oral immunosuppressant, azathioprine, mycophenolate or methotrexate.
Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.